Pamozirine | 1343476-98-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Pamozirine
• 英文别名: [4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]propanoyl]amino]phenyl]methyl (6S,6aS)-3-[5-[[(6aS)-2-methoxy-8-methyl-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-6-hydroxy-2-methoxy-8-methyl-11-oxo-6a,7-dihydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carboxylate
• CAS: 1343476-98-1
• 化学式: C₅₉H₇₀N₈O₁₄
• 分子量: 1115.2
• InChiKey: NHCHEHNZXVUCNF-PPNZEHHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  81
• 可旋转键数：
  25
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  264
• 氢给体数：
  4
• 氢受体数：
  15

文献信息

• NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE
  申请人：ABBVIE STEMCENTRX LLC

  公开号：US20190016812A1

  公开（公告）日：2019-01-17

  Provided are novel anti-TNFSF9 antibodies and antibody drug conjugates, and methods of using such anti-TNFSF9 antibodies and antibody drug conjugates to treat cancer.
• NOVEL ANTI-MMP16 ANTIBODIES AND METHODS OF USE
  申请人：ABBVIE STEMCENTRX LLC

  公开号：US20190022242A1

  公开（公告）日：2019-01-24

  Provided are novel anti-MMP16 antibodies and antibody drug conjugates, and methods of using such anti-MMP16 antibodies and antibody drug conjugates to treat cancer.
• NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
  申请人：ABBVIE STEMCENTRX LLC

  公开号：US20190083645A1

  公开（公告）日：2019-03-21

  Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
• ANTI-DLL3 DRUG CONJUGATES FOR TREATING TUMORS AT RISK OF NEUROENDOCRINE TRANSITION
  申请人：ABBVIE STEMCENTRX LLC

  公开号：US20190201542A1

  公开（公告）日：2019-07-04

  Methods of treating tumors at risk for neuroendocrine transition using anti-delta-like ligand 3 (DLL3) antibody drug conjugates (ADCs) are provided.
• [EN] ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENTS ANTI-DLL3 ET MÉTHODES D'UTILISATION
  申请人：ABBVIE STEMCENTRX LLC

  公开号：WO2017031458A2

  公开（公告）日：2017-02-23

  Provided are novel anti-DLL3 antibodies and antibody drug conjugates, and methods of using such anti-DLL3 antibodies and antibody drug conjugates to treat cancer.